Recent progress in the discovery of epigenetic inhibitors for the treatment of cancer

Methods in Molecular Biology

Volumn 1238, Issue , 2015, Pages 677-688

  Verma, Sharad K ^a  

^a NONE

Author keywords

Chromatin; Epigenetics; Histone methyltransferases; Nucleosome; Posttranslational modifi cation; S Adenosylmethionine (SAM)

Indexed keywords

HISTONE LYSINE METHYLTRANSFERASE; HISTONE LYSINE METHYLTRANSFERASE DOT1L; HISTONE LYSINE METHYLTRANSFERASE EZH2; HISTONE METHYLTRANSFERASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; DOT1L PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; METHYLTRANSFERASE; POLYCOMB REPRESSIVE COMPLEX 2;

ARTICLE; CANCER THERAPY; DNA SEQUENCE; EPIGENETICS; GENE TARGETING; GENETIC TRANSCRIPTION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; DRUG DISCOVERY; EPIGENESIS, GENETIC; HUMANS; METHYLTRANSFERASES; MOLECULAR TARGETED THERAPY; NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84955379914     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1804-1_35     Document Type: Article

References (47)

1. American Cancer Society (2013) Cancer Facts & Figures 2013. American Cancer Society, Atlanta
2. Kouzarides T (2007) Chromatin modifi cations and their function. Cell 128:693–705
3. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692
4. Wilson CB, Rowell E, Sekimata M (2009) Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 9:91–105
5. Tsankova N, Renthal W, Kumar A, Nestler EJ (2007) Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8:355–367
6. Copeland RA, Moyer MP, Richon VM (2013) Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene 32:939–946
7. Copeland RA, Solomon ME, Richon VM (2009) Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 8:724–732
8. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21–29
9. Cheng X, Zhang X (2007) Structural dynamics of protein lysine methylation and demethylation. Mutat Res 618:102–115
10. Dillon SC, Zhang X, Trievel RC (2005) The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol 6:227
11. Varambally S, Cao Q, Ram-Shankar M et al (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322:1695–1699
12. Varambally S, Dhanasekaran S, Zhou M et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629
13. Kleer CG, Cao Q, Varambally S et al (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100:11606–11611
14. Wagener N et al (2010) Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10:524
15. Takawa M, Masuda K, Kunizaki M et al (2011) Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102:1298–1305
16. Morin RD, Mendez-Lago M, Mungall AJ et al (2011) Frequent mutation of histonemodifying genes in non-Hodgkin lymphoma. Nature 476:298–303
17. Morin RD, Johnson NA, Severson TM et al (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:181–185
18. Pasqualucci L, Trifonov V, Fabbri G et al (2011) Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43:830–837
19. McCabe MT, Graves AP, Ganji G et al (2012) Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A 109: 2989–2994
20. Sneeringer CJ, Scott MP, Kuntz KW et al (2010) Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 107:20980–20985
21. Wigle TJ, Knutson SK, Jin L et al (2011) The Y641C mutation of EZH2 alters substrate specifi city for histone H3 lysine 27 methylation states. FEBS Lett 585:3011–3014
22. Yap DB, Chu J, Berg T et al (2011) Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117:2451–2459
23. Ernst T, Chase AJ, Score J et al (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42:722–726
24. Miranda TB, Cortez C, Yoo C et al (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8:1579–1588
25. Borchardt RT, Keller BT, Patel-Thombre U, Neplanocin A (1984) A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells. J Biol Chem 259:4353–4358
26. Chiang PK (1998) Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol Ther 77:115–134
27. Verma SK, Tian X, LaFrance LV et al (2012) Identifi cation of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett 3(12): 1091–1096
28. http://www.thesgc.org/scientists/chemical_probes
29. McCabe MT, Ott HM, Ganji G et al (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108–112
30. Qi W, Chan H, Teng L et al (2012) Selective inhibition of EZH2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 109(52):21360–21365
31. Knutson S, Wigle TJ, Warholic NM et al (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8:890–896
32. Nasveschuk CG, Gagnon A, Garapaty-Rao S et al (2014) Discovery and optimization of tetramethylpiperidine benzamides as inhibitors of EZH2. ACS Med Chem Lett 5:378-383
33. Garapaty-Rao S, Nasvechuk C, Gagnon A et al (2013) Identifi cation of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol 20:1–11
34. An open-label, multicenter, phase 1/2 study of E7438 (EZH2 histone methyl transferase [HMT] inhibitor) as a single agent in subjects with advanced solid tumors or with B cell lymphomas. NCT01897571
35. A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2816126 in subjects with relapsed/refractory diffuse large B cell and transformed follicular lymphoma. NCT02082977
36. Feng Q, Wang H, Ng HH et al (2013) Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 12:1052–1058
37. Daigle SR, Olhava EJ, Therkelsen CA et al (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20:53–65
38. Bernt KM, Zhu N, Sinha AU et al (2011) MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1LL. Cancer Cell 20:66–78
39. Daigle SR, Olhava EJ, Therkelsen CA et al (2013) Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122:1017–1025
40. http://clinicaltrials.gov/ct2/show/NCT01 684150?term=mixed+lineage+leukemia&ran k=1
41. Kim W, Bird G, Neff T et al (2013) Targeted disruption of the EZH2–EED complex inhib- its EZH2-dependent cancer. Nat Chem Biol 9:643–650
42. Verma SK, Kinght SD (2013) Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer. Future Med Chem 5:1661–1670
43. Allan M, Manku S, Therrien E et al (2009) N-benzyl-1-heteroaryl-3-(trifluoromethyl)- 1H-pyrazole-5-carboxamides as Inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). Bioorg Med Chem Lett 19: 1218–1223
44. Liu F, Chen X, Allali-Hassani A et al (2009) Discovery of a 2,4-diamino-7- aminoalkoxy quinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem 52:7950–7953
45. Liu F, Chen X, Allali-Hassani A et al (2010) Protein lysine methyltransferase g9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem 53:5844–5857
46. Ferguson AD, Larsen NA, Howard T et al (2011) Structural basis of substrate methylation and inhibition of SMYD2. Structure 19: 1262–1273
47. Vedadi M, Barsyte-Lovejoy D, Liu F et al (2011) A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 7:566–574